Downloads · 30 days
6
14% of all-time downloads
spidysense1337/surgdex-needlereach-e8
surgdex-needlereach-e8 is a robotics model from spidysense1337. Use it for the robotics task on the model card, and read the license before you ship it in a product. It is set up for gr00t. The card lists the license as apache-2.0.
GR00T-H-N1.7 fine-tuned for the SurRoL needlereach task (dexterous dVRK/PSM, vision-based closed-loop) as part of the SurgDex project.
Downloads · 30 days
6
14% of all-time downloads
All-time downloads
44
Public
Parameters
2.9B
11.8 GB on disk
Likes
0
Public
Click a slice to open those files.
.safetensors11.8 GB · 100%
From the Hugging Face model README
GR00T-H-N1.7 fine-tuned for the SurRoL needle_reach task (dexterous dVRK/PSM, vision-based closed-loop) as part of the SurgDex project.
This is the E8a checkpoint: fine-tuned on a zero-action-tail-trimmed LeRobot dataset with min-max action normalization, latent aux-head disabled, 15,000 steps.
needle_reach, H=8 receding horizon, denoise=16, N=25)| Metric | Value |
|---|---|
| success@reach (first step within threshold — receding-horizon reach controller) | 84% (21/25) |
| success@hold (strict: is_success at the end of the fixed 80-step horizon) | 0% (0/25) |
mean closest approach gmin | 0.020 (threshold = 0.025) |
The policy reliably reaches the goal (84%) but does not hold at it under the fixed-horizon strict metric: after reaching (~step 20) the arm drifts back toward the start, because the training episodes were trimmed to reach+3 steps and provide little "hold-at-goal" signal (and eval zeros the 4 latent state dims, an out-of-distribution condition at the goal). For a deployment that hands off to the next subtask on reach, success@reach is the operative metric.
A hold-tail retrain (E10b) targeting the strict success@hold is in progress: rebuild with a zero-action hold tail (zero-action fraction ~0.30 "sweet spot", vs 0.13 here and 0.67 in the undershooting predecessor E7), plus a latent-dropping ablation.
[0 : t_last+3] (zero-action fraction 0.673 → 0.134) removed the diluted flow-matching marginal (active-phase action mean is 2.66x larger) and cured the undershoot → 84% reach.Not a medical device. Research artifact only.